<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02792413</url>
  </required_header>
  <id_info>
    <org_study_id>UF9672</org_study_id>
    <nct_id>NCT02792413</nct_id>
  </id_info>
  <brief_title>Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease</brief_title>
  <acronym>HDENO</acronym>
  <official_title>Randomized Controlled Study Evaluating the Effect of a Biotherapy Treatment (Anti-RANKL Ligand Antibody: Denosumab) on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to evaluate in a population of old osteoporotic chronic kidney disease
      females the effect of denosumab:

        -  on bone mineral density (femoral T-score) at 24 months

        -  on bone mineral density evolution (femoral T-score) after 24 months of follow-up

        -  on bone mineral density evolution (lumbar T-score) after 24 months of follow-up

        -  on coronary and abdominal aorta calcification scores evolution after 24 months of
           follow-up

        -  on parameters of bone remodelling (OPG, RANKL, sclerostin, DKK-1), of mineral and
           calcium metabolism (FGF23 Ct, Klotho, PTH, 25(OH) vitamin D3, phosphorus, calcium, bone
           alklaline phosphatase, osteocalcin, CTX), of inflammation (CRP) after 24 months of
           follow-up

        -  on cardiovascular morbidity (cardiovascular events) and mortality after 24 months of
           follow-up

        -  the tolerance after 24 months of follow-up
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of this study is to evaluate in a population of old osteoporotic chronic kidney disease
      females the effect of denosumab:

        -  on bone mineral density (femoral T-score) (by bone densitometry) at 24 months

        -  on bone mineral density evolution (femoral T-score) (by bone densitometry) after 24
           months of follow-up

        -  on bone mineral density evolution (lumbar T-score) (by bone densitometry) after 24
           months of follow-up

        -  on coronary and abdominal aorta calcification scores evolution (by multiple detector
           computed tomography and plain abdominal X-ray) after 24 months of follow-up

        -  on parameters of bone remodelling (OPG, RANKL, sclerostin, DKK-1), of mineral and
           calcium metabolism (FGF23 Ct, Klotho, PTH, 25(OH) vitamin D3, phosphorus, calcium, bone
           alklaline phosphatase, osteocalcin, CTX), of inflammation (CRP) after 24 months of
           follow-up

        -  on cardiovascular morbidity (cardiovascular events) and mortality after 24 months of
           follow-up

        -  the tolerance after 24 months of follow-up
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative variation of femoral bone mineral density after 24 months of follow-up (T-score evaluated by osteodensitometry)</measure>
    <time_frame>24 months after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative variation of lumbar bone mineral density after 24 months of follow-up (T-score evaluated by osteodensitometry)</measure>
    <time_frame>24 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative variation of coronary calcification scores after 24 months of follow-up</measure>
    <time_frame>24 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative variation of abdominal aorta calcification scores after 24 months of follow-up</measure>
    <time_frame>24 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of calcium at 6, 12, 18 and 24 months of follow-up</measure>
    <time_frame>6, 12, 18 and 24 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of phosphorus at 6, 12, 18 et 24 months of follow-up</measure>
    <time_frame>6, 12, 18 and 24 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbi-mortality at 24 months of follow-up</measure>
    <time_frame>24 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events occuring during the entire study</measure>
    <time_frame>24 months after inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Female With Osteoporosis and Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Denosumab 60 mg, subcutaneous injection every 6 months for 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0.9% (1 mL), subcutaneous injection every 6 months for 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <arm_group_label>Denosumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl (placebo)</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient female of 65 years or older

          -  Chronic kidney disease stage 5 patient, hemodialyzed with extracorporeal treatment for
             at least 3 months

          -  History of vertebral fracture

        Exclusion Criteria:

          -  Cinacalcet treatment

          -  Substitutive hormonal treatment

          -  Calcium phosphate balance (PTH, 25(OH) vitamin D3, Calcium, phosphate) outside the
             KDIGO guidelines

          -  Hypersensibility to active substance or one of excipients of denosumab
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul CRISTOL, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Lapeyronie, Department of Biochemistry and Hormonology, Montpellier, FRANCE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Paul CRISTOL, Prof</last_name>
    <phone>+33(0)4 67 33 83 15</phone>
    <email>jp-cristol@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion MORENA, PhD</last_name>
    <phone>+33(0)4 11 75 98 93</phone>
    <email>m-morenacarrere@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Lyon Sud, Nephrology department</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denis Fouque, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Denis Fouque, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM, Nephrology department</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Brunet, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Brunet, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AIDER</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lotfi Chalabi, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Lotfi Chalabi, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier, Nephrology department</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georges Mourad, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Georges Mourad, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène Leray-Moragues, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leila Chenine, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice, Nephrology department</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Esnault, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Vincent Esnault, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nimes, Nephrology department</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal Reboul, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Pascal Reboul, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Perpignan, Nephrology department</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Vela, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Carlos Vela, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2016</study_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>anti-RANK ligand antibody</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>vascular calcifications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

